Matevž Srpčič
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Matevž Srpčič has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Andrej Janež
Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Center Ljubljana, Ljubljana, Slovenia
1 shared publication Karteek Popuri
Simon Fraser University , Burnaby , Canada
1 shared publicationM. Bitenc
Clinical Centre Ljubljana
1 shared publicationMihael Sok
Department of thoracic surgery, Surgical clinic, University Medical Centre Ljubljana , Ljubljana , Slovenia
1 shared publicationTaja Jordan
Institute of Radiology, University Medical Centre Ljubljana , Ljubljana , Slovenia
1 shared publication- Špela Volčanšek
University Medical Centre Ljubljana, Department of Endocrinology, Diabetes and Metabolic Diseases
1 shared publication
Latest Publications
- 24 June 2026
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Oncology
- Vol. 17 (6)
Letter to the Editor: Clinical consequences of body composition disturbances
I read with interest the retrospective cohort study by Xiao et al entitled “Body mass index predicts low muscle mass in esophageal squamous cell carcinoma patients undergoing chemoradiotherapy”. Body composition (BC) assessment is becoming an indispensable tool in clinical care. It provides data on patients’ nutritional and functional characteristics, helping clinicians determine prognosis and risk factors when planning treatment. Muscle loss is an independent negative prognostic factor in esophageal cancer. It has been associated with worse overall survival, worse quality of life and with increased incidence of complications during both surgical treatment and radical chemoradiotherapy. Recognizing patients with increased risk enables therapists to adjust treatment regimens and optimize nutritional support. Methods for evaluating BC have evolved rapidly in the last two decades. Traditional readily available measures such as body mass index and other anthropometrics are supplemented with advanced BC analysis techniques including planimetry (computed tomography or magnetic resonance imaging based BC scans), bioimpedance and emerging ultrasound BC analysis techniques. The pitfalls of misinterpreting body mass index in special scenarios such as sarcopenic obesity must be kept in mind as well as the intricate interplay between body mass, BC and their effects on outcomes. The obesity paradox needs further investigating focusing particularly on body mass, fat free body mass and muscle mass as measures of the actual functional reserve.
- 24 June 2026
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Oncology
- Vol. 17 (6)
Letter to the Editor: Clinical consequences of body composition disturbances
I read with interest the retrospective cohort study by Xiao et al entitled “Body mass index predicts low muscle mass in esophageal squamous cell carcinoma patients undergoing chemoradiotherapy”. Body composition (BC) assessment is becoming an indispensable tool in clinical care. It provides data on patients’ nutritional and functional characteristics, helping clinicians determine prognosis and risk factors when planning treatment. Muscle loss is an independent negative prognostic factor in esophageal cancer. It has been associated with worse overall survival, worse quality of life and with increased incidence of complications during both surgical treatment and radical chemoradiotherapy. Recognizing patients with increased risk enables therapists to adjust treatment regimens and optimize nutritional support. Methods for evaluating BC have evolved rapidly in the last two decades. Traditional readily available measures such as body mass index and other anthropometrics are supplemented with advanced BC analysis techniques including planimetry (computed tomography or magnetic resonance imaging based BC scans), bioimpedance and emerging ultrasound BC analysis techniques. The pitfalls of misinterpreting body mass index in special scenarios such as sarcopenic obesity must be kept in mind as well as the intricate interplay between body mass, BC and their effects on outcomes. The obesity paradox needs further investigating focusing particularly on body mass, fat free body mass and muscle mass as measures of the actual functional reserve.
- Open Access
- 1 January 2026
- Published by MDPI AG in Diabetology
- Vol. 7 (1) , 6
The Evolving Role of Continuous Glucose Monitoring in Hospital Settings: Bridging the Analytical and Clinical Needs
Background: The use of continuous glucose monitoring (CGM) offers several benefits. Compared to point-of-care (POC) capillary glucose tests, user acceptability is greater, and time in the target glucose range is improved. If these advantages can be transferred from outpatient to in-patient settings, CGM could assist clinicians in making timely, proactive treatment decisions. Scope of the review: This scoping review focuses on clinical studies of CGM use in hospital settings among non-pregnant adults, with a particular focus on studies from 2023 to 2025. It examines the latest evidence and guidelines and sets out the clinical and analytical considerations involved in implementing in-patient CGM. Main findings: In-hospital CGM facilitates hypoglycemia detection, especially asymptomatic and nocturnal episodes. Data on the impact of CGM use on clinical outcomes are scarce, and most studies focus on the reliability of CGM technology rather than clinical outcomes. Several factors affect CGM accuracy in hospitals, such as medications, fluid management, and hemodynamic disturbances. Despite between-device and settings-related variability, CGM devices generally show reasonable accuracy, with Mean Absolute Relative Differences (MARDs) ranging from 10% to 23%. In-hospital CGM has also improved workflows and reduced personnel exposure in infectious disease settings. Key implementation challenges: The MARD thresholds for safe in-hospital CGM use without confirmatory POC testing and evidence-based protocols for CGM application in ICU and non-ICU settings are not yet established. Despite challenges related to implementation, including personnel training, integrating diabetes technology with electronic health records, and costs, the benefits of improved monitoring and in-patient safety make CGM use worthwhile to pursue.
- 1 January 2026
- Published by MDPI AG in Diabetology
- Vol. 7 (1) , 6
Open AccessThe Evolving Role of Continuous Glucose Monitoring in Hospital Settings: Bridging the Analytical and Clinical Needs
Background: The use of continuous glucose monitoring (CGM) offers several benefits. Compared to point-of-care (POC) capillary glucose tests, user acceptability is greater, and time in the target glucose range is improved. If these advantages can be transferred from outpatient to in-patient settings, CGM could assist clinicians in making timely, proactive treatment decisions. Scope of the review: This scoping review focuses on clinical studies of CGM use in hospital settings among non-pregnant adults, with a particular focus on studies from 2023 to 2025. It examines the latest evidence and guidelines and sets out the clinical and analytical considerations involved in implementing in-patient CGM. Main findings: In-hospital CGM facilitates hypoglycemia detection, especially asymptomatic and nocturnal episodes. Data on the impact of CGM use on clinical outcomes are scarce, and most studies focus on the reliability of CGM technology rather than clinical outcomes. Several factors affect CGM accuracy in hospitals, such as medications, fluid management, and hemodynamic disturbances. Despite between-device and settings-related variability, CGM devices generally show reasonable accuracy, with Mean Absolute Relative Differences (MARDs) ranging from 10% to 23%. In-hospital CGM has also improved workflows and reduced personnel exposure in infectious disease settings. Key implementation challenges: The MARD thresholds for safe in-hospital CGM use without confirmatory POC testing and evidence-based protocols for CGM application in ICU and non-ICU settings are not yet established. Despite challenges related to implementation, including personnel training, integrating diabetes technology with electronic health records, and costs, the benefits of improved monitoring and in-patient safety make CGM use worthwhile to pursue.
- Open Access
- 27 March 2020
- Published by Walter de Gruyter GmbH in Radiology and Oncology
- Vol. 54 (2) , 237-246
Sarcopenia and myosteatosis at presentation adversely affect survival after esophagectomy for esophageal cancer
Background: Esophageal cancer remains a disease with poor survival and many complications. Measuring muscle mass and quality can identify patients with diminished muscle mass (sarcopenia) and muscle fat infiltration (myosteatosis). We studied the impact of sarcopenia and myosteatosis in resectable esophageal cancer on overall survival and complications. Patients and methods: 139 patients received a radical esophagectomy. Skeletal muscle area (SMA) and muscle attenuation (MA) in CT images at L3 level were recorded and groups with and without sarcopenia and myosteatosis were compared for overall survival (OS), perioperative mortality, conduit complications, pleuropulmonary complications, respiratory failure requiring mechanical ventilation and other significant complications. Results: Prevalence of sarcopenia and myosteatosis at presentation was 16.5% and 51.8%, respectively. Both were associated with decreased OS. Median survival was 18.3 months (CI 5.4–31.1) vs 31.0 months (CI 7.4–54.6) for sarcopenia/no sarcopenia (log rank p = 0.042) and 19.0 months (CI 13.3–24.7) vs 57.1 months (CI 15.2–99.0) for myosteatosis (log rank p = 0.044), respectively. A relationship between sarcopenia and myosteatosis and other negative outcomes after esophagectomy could not be established. Conclusions: Sarcopenia and myosteatosis before esophagectomy are associated with decreased overall survival but not with more frequent perioperative complications. Identification of patients at risk can guide therapeutic decisions and interventions aimed at replenishing muscle reserves.
- 27 March 2020
- Published by Walter de Gruyter GmbH in Radiology and Oncology
- Vol. 54 (2) , 237-246
Open AccessSarcopenia and myosteatosis at presentation adversely affect survival after esophagectomy for esophageal cancer
Background: Esophageal cancer remains a disease with poor survival and many complications. Measuring muscle mass and quality can identify patients with diminished muscle mass (sarcopenia) and muscle fat infiltration (myosteatosis). We studied the impact of sarcopenia and myosteatosis in resectable esophageal cancer on overall survival and complications. Patients and methods: 139 patients received a radical esophagectomy. Skeletal muscle area (SMA) and muscle attenuation (MA) in CT images at L3 level were recorded and groups with and without sarcopenia and myosteatosis were compared for overall survival (OS), perioperative mortality, conduit complications, pleuropulmonary complications, respiratory failure requiring mechanical ventilation and other significant complications. Results: Prevalence of sarcopenia and myosteatosis at presentation was 16.5% and 51.8%, respectively. Both were associated with decreased OS. Median survival was 18.3 months (CI 5.4–31.1) vs 31.0 months (CI 7.4–54.6) for sarcopenia/no sarcopenia (log rank p = 0.042) and 19.0 months (CI 13.3–24.7) vs 57.1 months (CI 15.2–99.0) for myosteatosis (log rank p = 0.044), respectively. A relationship between sarcopenia and myosteatosis and other negative outcomes after esophagectomy could not be established. Conclusions: Sarcopenia and myosteatosis before esophagectomy are associated with decreased overall survival but not with more frequent perioperative complications. Identification of patients at risk can guide therapeutic decisions and interventions aimed at replenishing muscle reserves.
- 1 December 2005
- Published by Springer Nature in European Surgery
- Vol. 37 (6) , 340-342
Subacute presentation of spontaneous diaphragmal rupture: a case report
- 1 December 2005
- Published by Springer Nature in European Surgery
- Vol. 37 (6) , 340-342
Subacute presentation of spontaneous diaphragmal rupture: a case report